October 2016 Newsletter
IASLC Board Creates the Fellowship Matching Challenge
The IASLC and IASLC Foundation Board Members have joined together to create the Fellowship Matching Challenge. Between now and December 31, the Board Members will match dollar for dollar any new or increased contributions up to $15,000.
As someone who wishes to be better educated about lung cancer, you understand the importance of people working to improve what is currently medically possible.
Since 2000, the IASLC has provided more than 80 researchers with fellowships. Fellowship grants have been awarded to medical doctors and scientists throughout the world, including Italy, the United States, Japan, Spain, Australia, France, China, Denmark, Ireland, Taiwan, Germany, Thailand, Poland, and Canada. We want to continue to grow these opportunities by awarding an increased number of fellowships to encourage even more groundbreaking research and worldwide collaboration.
IASLC Leads Development of Harmonized Lung Cancer Awareness Month (LCAM) Campaign
Over the past few months, the IASLC has been leading a harmonized public awareness campaign for November's Lung Cancer Awareness Month (LCAM). The centerpiece of this campaign is a brand-new website that IASLC has been developing, featuring images and stories from those who've been affected by lung cancer (including patients, family members, and advocates). The site will also point to promising advances in the field of lung cancer treatment and care that are enabling those affected to lead happier, healthier, and longer lives.
The lung cancer community can participate in this initiative by submitting personal stories to be included in the site. You can also sign up on the site to receive email updates about its continuing development.
IASLC Former President Nominated to ASCO Board of Directors
Tony Mok, the former president of the IASLC, has been nominated to the American Society of Clinical Society's (ASCO) Board of Directors. Read more about the nomination.
Meet the JTO Editor!
The Journal of Thoracic Oncology invites IASLC 17th World Conference on Lung Cancer (WCLC) attendees to meet with the Editor-in-Chief, Alex A. Adjei, MD, PhD, and the Managing Editor, Mary Todd.
Learn about manuscript submission, plans for the journal’s future, and provide feedback and suggestions. The session will be held on Monday, December 5 from 14:30-15:45.
Read the Third Issue of the IASLC Lung Cancer News
The third issue of the IASLC Lung Cancer News is now available online. This issue features:
To read the publication online simply follow this link, or download a PDF of the publication. The IASLC invites readers to submit article ideas, in addition to new content for future “Names and News” columns, to email@example.com. All submissions are subject to review and approval by the magazine’s editor, and selection for publication is not guaranteed.
Academic, Career, and Funding Opportunities
As a service to our members, we post opportunities related to lung cancer and other thoracic malignancies on our website.
This now includes academic career opportunities. Click here to review post-doctoral and other career opportunities submitted to IASLC. If you have an academic career opportunity, please email it to firstname.lastname@example.org.
We also post opportunities when we receive information from grantors. We currently have five funding opportunities:
These opportunities are available to applicants from all countries. Click here to learn more.
Social Media Corner: Are You a Tweeter, Facebooker,YouTuber, WeChater or Instagramer?
Anne-Marie Baird, Senior Research Fellow, St. James's Hospital, Dublin
During the year, this column has concentrated quite a bit on Twitter and Facebook. However, social media can be anything from A to Z as outlined in this recent article from Times Higher Education. What you use comes down to personal preference, and, of course, the time you have available to cultivate an online presence. Some people may favor the 140 character route, while others might prefer something more visual like Instagram. Another factor to consider is location, as usage can vary widely depending on the country. Facebook may be extensively used in America; however, WeChat is widely used in China, Line is common in Japan, and Vk (formally VKontakte) is popular in Russia.
No matter which channel you prefer, they can all be used in the pursuit of our mutual goals: building our lung cancer community; supporting patients, caregivers, advocacy, and research; and increasing awareness for the disease and participation in clinical trials. The more people that are active, the more we can rise above the social media noise and make a lasting impact. This is something to consider during Lung Cancer Awareness Month (LCAM) in November. If you would like to get involved and share your story during LCAM you can do so here.
October 2016: The IASLC and the Journal of Thoracic Oncology (JTO) are pleased to present the Editor's Choice each month to highlight certain articles of interest. The selected articles will be made available to the public for a limited time upon printing. The articles below from the October issue of the JTO are free for three months. Please share with your colleagues around the globe!
Alex A. Adjei, MD, PhD
With the development of a number of kinase inhibitors that have significant efficacy against a number of protein products of oncogenic drivers in lung cancer, such as EGFR, ALK, ROS1, BRAF, MET, RET and TRK, acquisition of lung tissue for genomic analysis in order to direct effective therapy has become the standard of care.
However, in a number of cases obtaining adequate lung tissue safely for analysis is challenging. The development of blood- based analyses of tumor tissue or “liquid biopsies” have been studied intensely over the last few years. Two of the important blood components that have been studied are highlighted this month.
A Brief Report: Circulating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein are Associated with Disease Recurrence After Surgical Resection of Non-Small Cell Lung Cancer
Crosbie and colleagues enumerate circulating tumor cells in the tumor draining pulmonary vein of resected lung cancer as a predictor of disease recurrence.
A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma
This report describes a platform for detection of EGFR mutations in lung cancer patients through analysis of circulating DNA in plasma and urine.
These articles are accompanied by an insightful editorial by Dr. Jie Wang and her colleague.
Postoperative Radiation Therapy is Associated with Longer Overall Survival in Completely Resected Stage II and III Thymoma - An Analysis of the International Thymic Malignancies Interest Group (ITMIG) Retrospective Database
Because of the rarity of thymoma, large prospective studies to guide therapeutic decisions are largely lacking. However, the International Thymic Malignancies Interest Group (ITMIG) has compiled a large database which provides the best evidence available to make therapeutic decisions. This article by Rimner and colleagues presents an analysis of the ITMIG database which demonstrates the survival benefit of post-operative radiation in completely resected stage II and III thymoma.
EGFR TKIs Plus WBRT Demonstrated No Survival Benefit Than TKIs Alone in NSCLC Patients with EGFR mutation and Brain Metastases
Brain metastases in EGFR mutant NSCLC patients is a common problem whose ideal management is still being studied. In a provocative study, Zhou and colleagues demonstrate that the addition of WBRT to EGFR TKIs does not confer any additional benefit to utilizing EGFR TKIs alone. There is a thoughtful accompanying editorial by Dr. Dziadziuszko.
The following article was selected from the JTO by the IASLC Communications Committee to be promoted to the media and the public with a press release that was released at the time of online publication (Published Ahead of Print).
To read more IASLC Press Releases, please visit IASLC Research Articles. These press releases are also announced via social media, so please follow IASLC on Twitter, LinkedIn, and Facebook to stay up to date on the latest scientific topics.
The combined use of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC) identified non-small cell lung cancer (NSCLC) patients with rare or novel anaplastic lymphoma kinase (ALK) gene rearrangements, not otherwise identified by FISH alone, that showed response to crizotinib treatment.
Member Discount for IASLC 17th World Conference on Lung Cancer
To find your Member ID in your IASLC account:
1. Login. Enter your Username and Password. If you have forgotten your password, you can always reset it with the “Forgot Password” button on your screen. Once signed into your account, click “My Details” on the right side of your screen. You will then see your Member ID appear towards the top of your screen.
2. You will also find your Member ID in any past renewal email notices, invoices, or on your Member ID Card from IASLC. However, please feel free to email email@example.com and we will be happy to provide your Member ID to you right away.
Member Account Information
Free Membership for Patients/Survivors
The IASLC has a free membership option for patients and survivors of any thoracic malignancy. All patients/survivors with a diagnosis of lung cancer, mesothelioma, or other thoracic cancer qualify for this free membership. Patients and survivors can renew this non-voting membership annually. Except for voting, the patient/survivor membership includes all Allied Health Professional member benefits, and includes online access to the JTO, member meeting discounts, eligibility to apply for travel awards, and eligibility to serve on committees. Register as Patient/Survivor.
Become a Member
Join the only international association solely dedicated to lung cancer research and treatment.
WCLC Virtual Library
February 20 - 23 2019Santa Monica, California
April 3 - 5 2019New York, New York
April 10 - 13 2019Geneva, Switzerland